Search clinical trials for: HFA FP MDI

Total 6809 results

Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
University of Washington
AstraZeneca

Terminated

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Boehringer Ingelheim

Completed

Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers

Healthy
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Russell Richardson

Recruiting

: Vascular Function in Health and Disease

Heart Failure | Hypertension | Chronic Obstructive Pulmonary Disease | Pulmonary Artery Hypertension

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditions

United States
The University of Texas Medical Branch, Galveston
National Institutes of Health (NIH); National Institute of General Medical... and other collaborators

Terminated

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Burns

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor | Recurrent Kidney Wilms Tumor | Anaplastic Kidney Wilms Tumor

United States, Canada, Puerto Rico, Australia, New Zealand, Saudi Arabia
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
University of Washington
Genzyme, a Sanofi Company

Recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Active, not recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
University of Washington
AstraZeneca

Withdrawn

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

Hydatidiform Mole | Choriocarcinoma | FIGO Stage I Gestational Trophoblastic Tumor | FIGO Stage II Gestational Trophoblastic Tumor | FIGO Stage III Gestational Trophoblastic Tumor

United States, Korea, Republic of, Canada, Japan, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive)...

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States, Guam
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Hepatoblastoma | Fibrolamellar Carcinoma | Childhood Hepatocellular Carcinoma | Childhood Malignant Liver Neoplasm | Hepatocellular Malignant Neoplasm, Not Otherwise Specified

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
Fred Hutchinson Cancer Center

Recruiting

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Suspended

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | CD20 Positive | Aggressive Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Unclassifiable | Intravascular Large B-Cell Lymphoma | T-Cell/Histiocyte-Rich...

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand
Fred Hutchinson Cancer Center

Recruiting

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Suspended

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States

Search clinical trials for: HFA FP MDI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations